Abstract |
The effect of verapamil on death, reinfarctions, and major events i.e. reinfarction or death, has been investigated in two Danish double-blind, placebo-controlled verapamil infarction trials DAVIT I and II. DAVIT I, which was an early intervention trial, demonstrated that after six months there was a statistically non-significant reduction of mortality and reinfarction. DAVIT II demonstrated a non-significant reduction of mortality rate (P = 0.11, hazard ratio 0.80, 95% confidence limits 0.61-1.05), a significant reduction of reinfarction rate (P = 0.04, 0.77, 0.58-1.03), and major event rate (P = 0.03, 0.80, 0.64-0.99) in the verapamil group compared with the placebo group. Meta-analyses of DAVIT I (including only patients alive on day eight) and of DAVIT II showed a statistically significant reduction of odds ratio of mortality of 22% (P = 0.04), of reinfarctions of 27% (P = 0.02), and of major events of 21% (P = 0.02). It is concluded that long-term treatment with verapamil after an acute myocardial infarction is associated with a significant reduction in overall mortality, major events, and reinfarction rates.
|
Authors | |
Journal | Journal of human hypertension
(J Hum Hypertens)
Vol. 4 Suppl 5
Pg. 19-25
(Dec 1990)
ISSN: 0950-9240 [Print] England |
PMID | 2090834
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Verapamil
|
Topics |
- Anti-Arrhythmia Agents
(metabolism, therapeutic use)
- Antihypertensive Agents
(adverse effects, therapeutic use)
- Coronary Disease
(prevention & control)
- Death, Sudden
- Denmark
(epidemiology)
- Double-Blind Method
- Humans
- Myocardial Infarction
(drug therapy, epidemiology, mortality)
- Verapamil
(adverse effects, therapeutic use)
|